Date: 2016-05-10
Type of information: Opening of new premises
Compound: biopharmaceutical manufacturing facility in Wuhan
Company: JHL Biotech (Taiwan)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On May 10, 2016, JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China. JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars and monoclonal antibodies (mAbs) for late–stage clinical trials and commercial supply. The facility will also provide process development and manufacturing services for JHL’s global customer base.
JHL and GE Healthcare partnered to complete the construction of the facility in just 18 months using GE’s KUBio manufacturing solution. KUBio is a prefabricated cGMP-compliant facility and process solution designed for scalable and cost-efficient manufacturing.
Financial terms:
Latest news:
